GoAI
Get started
Lisata Therapeutics, Inc. logo

Lisata Therapeutics, Inc.

LSTA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$1.55

+$0.43 · +38.39%

Aug 21, 3:55 PM ET

LSTA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

21

Expensive

Momentum

45

Neutral

Sentiment

50

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
David J. Mazzo
Listed since
Mar 1, 1999
Employees
21

Market position

Volume
7.12M
37.82× average
Average volume
188.27K
Average daily volume
Market cap
14.11M USD
Beta
0.8
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.95×
P/B (TTM)
1.71×
P/S (TTM)
141.15×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
95.00%
Operating margin
-16427.00%
Net margin
-14621.00%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1181%-3143%-7468%-11792%Gross margin, FY2024: 100.00%Gross margin, FY2025: 14.12%Operating margin, FY2024: -2240.90%Operating margin, FY2025: -10711.18%Net margin, FY2024: -1998.50%Net margin, FY2025: -9756.47%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 14.12%. Operating margin FY2024 -2240.90%. Operating margin FY2025 -10711.18%. Net margin FY2024 -1998.50%. Net margin FY2025 -9756.47%.

Income trends

Revenue

170K USD-83.00%

Operating income

−18.21M USD+18.74%

Net income

−16.59M USD+17.01%
Income trends across reported periods6.86M USD−16.58M USD−40.02M USD−63.46M USDRevenue, FY2024: 1M USDRevenue, FY2025: 170K USDOperating income, FY2021: −29.05M USDOperating income, FY2022: −57.6M USDOperating income, FY2023: −25.71M USDOperating income, FY2024: −22.41M USDOperating income, FY2025: −18.21M USDNet income, FY2021: −27.47M USDNet income, FY2022: −54.23M USDNet income, FY2023: −20.84M USDNet income, FY2024: −19.99M USDNet income, FY2025: −16.59M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 1M USD. Revenue FY2025 170K USD. Operating income FY2021 −29.05M USD. Operating income FY2022 −57.6M USD. Operating income FY2023 −25.71M USD. Operating income FY2024 −22.41M USD. Operating income FY2025 −18.21M USD. Net income FY2021 −27.47M USD. Net income FY2022 −54.23M USD. Net income FY2023 −20.84M USD. Net income FY2024 −19.99M USD. Net income FY2025 −16.59M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue170K USD1M USD———
Cost of goods sold146K USD————
Gross profit24K USD1M USD———
Research and development7.95M USD11.33M USD12.73M USD43.46M USD17.58M USD
Selling, general, and administrative10.43M USD12.08M USD12.97M USD14.14M USD11.47M USD
Operating expenses18.23M USD23.41M USD25.71M USD57.6M USD29.05M USD
Interest income806K USD1.88M USD2.72M USD1.05M USD151K USD
Depreciation and amortization146K USD174K USD189K USD69K USD55K USD
Operating income−18.21M USD−22.41M USD−25.71M USD−57.6M USD−29.05M USD
Net income−16.59M USD−19.99M USD−20.84M USD−54.23M USD−27.47M USD

Company facts updated Aug 24, 2026.

LSTA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding LSTA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
189.46K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
79.64K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Dimensional - US Sustainability Core 1 ETF logoDimensional - US Sustainability Core 1 ETFDFSU
Market value
155
Weight
0.00%
AUM
2.35B USD
Expense ratio
0.15%
Price / 1D
$48.20+0.52%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
12.4
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54+0.42%

Continue in GoAI

Research LSTA

research.disclaimer